Cytomel (Liothyronine) Cost in Wisconsin 2026

What Is Liothyronine and Why Is It Prescribed in Wisconsin?

Liothyronine is the synthetic form of triiodothyronine (T3), the metabolically active thyroid hormone that cells use directly. Physicians prescribe it when levothyroxine (T4) monotherapy leaves patients symptomatic, when T4-to-T3 conversion is impaired, or as suppression therapy in differentiated thyroid cancer. The FDA approved Cytomel (liothyronine sodium) tablets; the current prescribing information is maintained on the FDA Drugs@FDA database [1].

T3 is roughly four times more potent than T4 on a microgram-for-microgram basis. Standard starting doses in adults range from 25 mcg daily up to 75 mcg daily in divided doses, titrated against serum TSH and free T3 [2]. Because T3 has a short half-life of about 24 hours compared to levothyroxine's 7-day half-life, twice-daily dosing is common in clinical practice [3].

The landmark trial by Bunevicius et al. (NEJM 1999, N=33) reported that substituting 12.5 mcg of T3 for 50 mcg of T4 in the daily levothyroxine dose produced statistically significant improvements in mood, neuropsychological testing scores, and preference in hypothyroid patients compared to T4-alone (P<0.001) [4]. That study reshaped prescribing patterns and remains the most cited randomized evidence for combination T3/T4 therapy. Later meta-analyses have been more cautious: a 2019 Cochrane-style systematic review in the Journal of Clinical Endocrinology and Metabolism (JCEM) found that combination therapy improved patient preference over T4 monotherapy in some but not all trials, with no consistent superiority on quality-of-life scales [5].

The American Thyroid Association's 2014 guidelines note that "combination T4/T3 therapy may be appropriate for a subset of hypothyroid patients" and recommend individualized decision-making [6]. Wisconsin prescribers operate under these national standards, meaning there is no state-specific restriction that limits who may receive a liothyronine prescription.

Exact 2026 Liothyronine Prices at Wisconsin Pharmacies

Generic liothyronine costs about $35 per month at Wisconsin retail pharmacies when patients pay cash or use a free discount card. Brand-name Cytomel carries a manufacturer list price near $120 per month before any insurance adjustment.

Prices vary by tablet strength and quantity. A 30-count supply of 25 mcg generic liothyronine averages $18 to $22 at major Wisconsin chains including Walgreens, CVS, and Hy-Vee when a GoodRx coupon is applied at checkout. The 5 mcg tablet in a 60-count supply (common for titration) runs closer to $28. Splitting a 25 mcg tablet to achieve 12.5 mcg doses is sometimes done in practice, but liothyronine tablets are not scored, and the FDA cautions against splitting unscored tablets for precise dosing [1].

Cash prices shift between ZIP codes. Rural Wisconsin counties (for example, Burnett and Iron counties) tend to have fewer competing pharmacies, which can push independent pharmacy prices 15 to 25 percent above Madison or Milwaukee chain prices. Using GoodRx or RxSaver at an in-network location is the single fastest way to confirm the current price at a specific pharmacy before picking up the prescription [7].

Pfizer's Cytomel brand is rarely the default dispense at Wisconsin pharmacies because generic substitution is permitted under Wisconsin Statute 450.13, which allows pharmacists to substitute any therapeutically equivalent generic unless the prescriber writes "dispense as written." Brand Cytomel becomes relevant mainly when a patient has documented intolerance to one of the inactive excipients in a particular generic formulation.

The table below summarizes 2026 Wisconsin price benchmarks:

| Product | Strength | Qty | Est. Cash Price (WI) | |---|---|---|---| | Generic liothyronine | 25 mcg | 30 tabs | ~$20 | | Generic liothyronine | 25 mcg | 90 tabs | ~$45 | | Generic liothyronine | 5 mcg | 60 tabs | ~$28 | | Cytomel (brand) | 25 mcg | 30 tabs | ~$120 | | Compounded liothyronine T3 | custom mcg | 30-day | ~$40 |

Wisconsin Medicaid Coverage for Liothyronine

Wisconsin Medicaid (ForwardHealth) covers liothyronine with prior authorization (PA). Generic liothyronine appears on the ForwardHealth preferred drug list; the PA requirement typically applies to brand Cytomel rather than to the generic.

To obtain PA for brand Cytomel under ForwardHealth, the prescriber generally must document a clinical reason for brand-specific dispensing, such as an adverse reaction to a specific generic's inactive ingredients or demonstrated bioavailability issues. The ForwardHealth PA process is completed through the online portal or by fax, and decisions are usually returned within 24 to 72 business hours [8].

Generic liothyronine, by contrast, often processes as a straightforward fill under ForwardHealth without PA when the diagnosis code (ICD-10 E03.9 for hypothyroidism, unspecified, or E89.0 for post-procedural hypothyroidism) is transmitted on the claim. Prescribers should verify the current preferred drug list at the ForwardHealth provider portal because formulary status is updated quarterly [8].

Wisconsin Medicaid enrollees with dual Medicare/Medicaid eligibility (dually eligible beneficiaries) may access liothyronine through a Medicare Part D plan instead. Most Part D formularies place generic liothyronine on Tier 1 or Tier 2, meaning the beneficiary cost-share is typically $0 to $10 per 30-day supply [9].

The Wisconsin Well Woman Program and state family-planning waiver do not cover thyroid medications, so patients relying on those limited benefit programs must use a separate pathway.

Is Compounded Liothyronine Legal in Wisconsin?

Compounded liothyronine T3 is legal in Wisconsin when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. No federal or Wisconsin-specific ban exists on T3 compounding.

The FDA's framework for compounded drugs divides pharmacies into 503A (traditional, patient-specific compounding) and 503B (outsourcing facilities, bulk supply). A 503A pharmacy may compound liothyronine T3 in custom strengths, alternative delivery forms such as sublingual troches, or combination T3/T4 capsules when a licensed prescriber issues a prescription with a documented clinical rationale for the non-commercially available formulation [10].

Wisconsin's Pharmacy Examining Board licenses 503A pharmacies under Wis. Admin. Code Phar ch. 7. Compounding pharmacies must meet USP 795 standards for non-sterile preparations, which cover potency, sterility (where applicable), and beyond-use dating. Patients who receive compounded liothyronine should confirm their pharmacy holds an active Wisconsin license through the Wisconsin Department of Safety and Professional Services (DSPS) license lookup tool.

Compounded liothyronine costs about $40 per month from licensed Wisconsin 503A pharmacies, slightly above the $35 generic retail benchmark. The premium reflects the labor and quality-testing overhead of custom compounding. Some patients accept this cost because compounding allows:

1. Strengths not commercially available (for example, 10 mcg tablets for fine titration).
2. Dye-free or lactose-free formulations for patients with documented excipient sensitivities.
3. Sustained-release T3 preparations, though the clinical evidence base for SR-T3 remains limited and the FDA has not approved any sustained-release liothyronine product [10].

Insurance reimbursement for compounded liothyronine is inconsistent. Most commercial plans and Wisconsin Medicaid do not cover compounds when an FDA-approved equivalent exists, which means patients generally pay out of pocket.

Telehealth Prescribing of Liothyronine in Wisconsin

Wisconsin permits telehealth prescribing of liothyronine by licensed Wisconsin prescribers. The state's telehealth parity law (2015 Wis. Act 157) requires private insurers to cover telehealth services on the same basis as in-person visits, which extends to the consultation that generates a liothyronine prescription [11].

Liothyronine is not a controlled substance under the federal Controlled Substances Act or Wisconsin's Uniform Controlled Substances Act, so there is no Ryan Haight Act restriction requiring an in-person examination before prescribing. A physician, advanced practice nurse prescriber (APNP), or physician assistant (PA-C) licensed in Wisconsin may prescribe liothyronine after a synchronous audio-video telehealth encounter and review of thyroid function labs [11].

For a first-time liothyronine prescription via telehealth, best practice requires:

• A recent TSH (within 3 months) and free T4 measurement.
• Free T3 if available, to establish the pre-treatment T3 level.
• A clinical note documenting why liothyronine is indicated over levothyroxine adjustment alone.

HealthRX telehealth providers serving Wisconsin patients follow this protocol. Follow-up TSH and free T3 checks at 6 to 8 weeks after any dose change are standard, matching the American Thyroid Association's 2014 recommendation that thyroid function testing occur at least 6 weeks after initiation or dose adjustment [6].

Telehealth consultations for liothyronine management typically run $75 to $150 for a new patient visit on cash-pay platforms, with follow-up visits at $45 to $75. Wisconsin's Medicaid telehealth parity rules mean ForwardHealth enrollees may access telehealth thyroid consultations at the same cost-share as in-person visits [8].

Insurance Coverage for Liothyronine in Wisconsin

Most Wisconsin commercial insurance plans cover generic liothyronine. Brand Cytomel coverage depends on the specific plan's formulary.

Wisconsin's largest commercial carriers, Anthem/Blue Cross Blue Shield of Wisconsin, Quartz, Common Ground Healthcare Cooperative, and Molina Healthcare of Wisconsin, all include generic liothyronine on their standard formularies, typically at Tier 1 ($0 to $15 copay) or Tier 2 ($20 to $45 copay) [12]. Confirming tier placement requires checking the specific plan's current formulary because tiers are renegotiated annually during open enrollment.

Prior authorization requirements for brand Cytomel are common across Wisconsin commercial plans. Step therapy (requiring a trial of generic liothyronine first) is sometimes imposed. If a prescriber believes brand-specific dispensing is medically necessary, a PA request documenting the clinical rationale and previous generic trial should accompany the submission.

Patients who exhaust the PA process without approval may appeal. Wisconsin's Insurance Commissioner (OCI) allows external independent review of PA denials for medically necessary services under Wis. Stat. 632.835. The external reviewer's decision is binding on the insurer. Patients have 180 days from a denial to file an external review request [13].

Medicare Part D plans in Wisconsin, there are over 20 standalone Part D plans available in the state for 2026, uniformly place generic liothyronine on low-cost tiers. The 2026 Medicare Part D redesign caps out-of-pocket drug spending at $2,000 per year, which limits maximum annual exposure for liothyronine even if a plan prices it at a higher tier [9].

Discount Programs and the Cheapest Way to Get Liothyronine in Wisconsin

The cheapest reliable path for most Wisconsin patients is a GoodRx coupon applied to a 90-day supply of 25 mcg generic liothyronine at a high-volume chain pharmacy, which reduces cost to roughly $45 per quarter ($15 per month).

GoodRx and RxSaver are free to use and accepted at virtually every Wisconsin chain pharmacy. Neither requires enrollment or income verification. Patients present the coupon on their phone at the pharmacy counter; the price shown on the coupon website is the price charged. GoodRx prices for liothyronine 25 mcg at Wisconsin Walgreens and CVS locations have been tracking between $16 and $24 for a 30-count supply through early 2025 [7].

Pfizer's Cytomel savings card applies only to brand-name Cytomel. Eligible commercially insured patients (Medicare and Medicaid excluded) may pay as little as $0 to $25 per month. The savings card is available through the Pfizer patient assistance portal; patients must verify eligibility and activate the card before their first brand fill [14]. Income-qualified patients without insurance may qualify for Pfizer's RxPathways program, which can supply brand Cytomel at no cost through a prescriber-initiated enrollment process [14].

Generic manufacturer patient assistance programs (PAPs) exist but are less common for low-cost generics. The NeedyMeds database lists state and manufacturer programs; Wisconsin residents with incomes below 200 percent of the federal poverty level should search NeedyMeds before assuming no assistance is available [15].

Wisconsin's SeniorCare program (for residents aged 65 and older) covers prescription drugs including liothyronine with a $30 annual enrollment fee and a $5 copay per generic prescription. Enrollment income limits are updated annually; the income ceiling for a single applicant in 2025 was $29,920 [16].

Splitting a 25 mcg tablet to achieve 12.5 mcg doses looks attractive from a cost standpoint because the 25 mcg and 5 mcg tablets are often priced similarly. However, since liothyronine tablets are not scored, dose accuracy after splitting is unreliable. Patients requiring 12.5 mcg doses should either obtain a compounded product or ask their prescriber whether 25 mcg once daily is an acceptable alternative target [1].

Monitoring Requirements and Clinical Context

Liothyronine monitoring differs from levothyroxine monitoring. Patients need to understand this.

Because T3 has a short half-life, serum free T3 fluctuates throughout the day. Blood draws should be timed consistently, ideally 2 to 4 hours after a dose, to allow meaningful comparison across visits [6]. TSH is still used as a primary monitoring parameter, but TSH may be suppressed below the reference range in patients taking any exogenous T3, even at physiologic replacement doses, without indicating over-replacement [3].

The American Thyroid Association's 2014 hypothyroidism management guidelines recommend annual TSH testing once patients are stable on a fixed liothyronine dose, with more frequent testing (every 6 to 8 weeks) after any dose change [6]. Free T3 measurement adds information about circulating hormone levels but is not universally required at every monitoring visit.

Cardiac monitoring deserves specific mention. Liothyronine in excess accelerates heart rate and can precipitate or worsen atrial fibrillation. The FDA label for Cytomel contraindicates use in patients with uncorrected adrenal cortical insufficiency and states that doses should be titrated cautiously in patients with cardiovascular disease [1]. A 2020 cohort analysis published in Thyroid (N=32,639) found that patients on combination T3/T4 therapy had a 23 percent higher rate of atrial fibrillation diagnoses over 3 years compared to T4-monotherapy patients, though confounding by indication was acknowledged as a limitation [17]. Wisconsin prescribers managing patients with pre-existing arrhythmias should document a cardiac risk-benefit discussion before initiating liothyronine.

Bone health is a secondary concern. Exogenous thyroid hormone at suppressive doses is associated with decreased bone mineral density, particularly in postmenopausal women. A meta-analysis in JAMA Internal Medicine (2015) found TSH suppression therapy was associated with a relative risk of hip fracture of 1.38 (95% CI 1.16 to 1.65) compared to euthyroid control groups [18]. Patients on liothyronine who are postmenopausal or have osteopenia should have periodic DEXA scans per standard osteoporosis screening guidelines.